Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.

@article{Verweel2007PlasmaCO,
  title={Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.},
  author={Gwenda Verweel and David M Burger and Nancy L Sheehan and Alina S Bergshoeff and Adilia Warris and Linda C van der Knaap and Gertjan J. A. Driessen and Ronald de Groot and Nico G. Hartwig},
  journal={Antiviral therapy},
  year={2007},
  volume={12 4},
  pages={453-8}
}
BACKGROUND Lopinavir/ritonavir (LPV/r) has been licensed for the treatment of HIV-infected children >6 months in the US and >2 years in the EU. Limited LPV paediatric pharmacokinetic data are available. We studied LPV pharmacokinetics to determine whether the recommended dose (230/57.5 mg/m2 twice daily) results in optimal LPV exposure in all age groups. Virological efficacy was a secondary objective. METHODS HIV-1-infected children who started treatment with LPV/r and two nucleoside reverse… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…